Immunomedics strives to improve health care and extend life by focusing on the development and commercialization of humanized monoclonal antibody-based treatments for cancer, autoimmune and other serious diseases. The Food and Drug Administration recently fast tracked the company s leading drug candidate, Epratuzumab for the potential treatment of the world s estimated 3 million sufferers of lupus. Immunomedics is traded publicly on NASDAQ under the symbol IMMU and maintains corporate headquarters in Morris Plains, N.J.
Partial Data by Infogroup (c) 2024. All rights reserved.